Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl J Med. 2017;376:1311–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32:309–22.

Article  CAS  PubMed  Google Scholar 

Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gillich C, Akhoundova D, Hayoz M, Aebi Y, Largiadèr CR, Seipel K, et al. Efficacy and safety of high-dose chemotherapy with treosulfan and melphalan in multiple myeloma. Cancers. 2023;15:2699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farag S, Bacher U, Jeker B, Legros M, Rhyner G, Lüthi JM, et al. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: a randomized phase-2 trial. Bone Marrow Transpl. 2022;57:990–7.

Article  CAS  Google Scholar 

Bensinger WI. The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Cancer Netw. 2004;2:371–8.

Article  Google Scholar 

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl J Med. 2003;348:1875–83.

Article  CAS  PubMed  Google Scholar 

Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transpl. 2013;48:1279–84.

Article  CAS  Google Scholar 

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy‐era with plerixafor and G‐CSF has superior efficacy but significantly higher costs compared to mobilization with low‐dose cyclophosphamide and G‐CSF. J Clin Apher. 2013;28:359–67.

Article  PubMed  Google Scholar 

Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, et al. Efficacy of vinorelbine plus granulocyte colony–stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biol Blood Marrow Transplant. 2015;21:74–80.

Article  CAS  PubMed  Google Scholar 

Jeker B, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller BU, et al. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Bone Marrow Transpl. 2018;53:175–9.

Article  CAS  Google Scholar 

Jeker B, Farag S, Taleghani BM, Novak U, Mueller BU, Li Q, et al. A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients. Bone Marrow Transpl. 2020;55:2047–51.

Article  Google Scholar 

Bühler S, Akhoundova D, Jeker B, Legros M, Seipel K, Daskalakis M, et al. Stem cell mobilization with Ixazomib and G-CSF in patients with multiple myeloma. Cancers. 2023;15:430.

Article  PubMed  PubMed Central  Google Scholar 

Keller S, Seipel K, Novak U, Mueller BU, Taleghani BM, Leibundgut K, et al. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Leuk Res. 2015;39:786–92.

Article  CAS  PubMed  Google Scholar 

Pace A, Bove L, Nistico C, Ranuzzi M, Innocenti P, Pietrangeli A, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry. 1996;61:409–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mueller BU, Keller S, Seipel K, Mansouri Taleghani B, Pabst T. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib induced neurotoxicity. Blood. 2015;126:5436.

Article  Google Scholar 

DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.

Article  CAS  PubMed  Google Scholar 

Schmid A, Friess D, Mansouri Taleghani B, Keller P, Mueller BU, Baerlocher GM, et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma. 2015;56:608–14.

Article  CAS  PubMed  Google Scholar 

Bilgin YM. Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantations: an update. J Blood Med. 2021 12:403–12.

Article  PubMed  PubMed Central  Google Scholar 

Maechler M, Bacher U, Daskalakis M, Nilius H, Nagler M, Taleghani BM, et al. Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients. Hematol Oncol. 2023;41:583–6.

Article  CAS  PubMed  Google Scholar 

Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transpl. 2009;43:619–25.

Article  CAS  Google Scholar 

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, et al. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transpl. 2018;53:1116–23.

Article  CAS  Google Scholar 

Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transpl. 2003;31:99–103.

Article  CAS  Google Scholar 

Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, et al. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis. Transfus Apheresis Sci. 2020;59:102819.

Article  CAS  Google Scholar 

Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:35.

Article  PubMed  PubMed Central  Google Scholar 

Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer. 1995;31:2260–3.

Article  Google Scholar 

Boonstra AM, Stewart RE, Köke AJA, Oosterwijk RFA, Swaan JL, Schreurs KMG, et al. Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol. 2016;7. https://doi.org/10.3389/fpsyg.2016.01466.

International Myeloma Foundation. https://www.myeloma.org/autologous-stem-cell-transplant (accessed 12 Mar 2024).

Li Y, Qiu X, Lei Y, Zhou R. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Ann Med. 2024;56:2329140.

Article  PubMed  PubMed Central  Google Scholar 

Sarıcı A, Erkurt MA, Bahçecioğlu ÖF, Gök S, Kuku İ, Biçim S, et al. Filgrastim alone versus cyclophosphamide and filgrastim for mobilization in multiple myeloma patients. Transfus Apher Sci. 2021;60. https://doi.org/10.1016/j.transci.2021.103159.

Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, et al. Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +/− plerixafor versus granulocyte colony-stimulating factor +/− plerixafor in the lenalidomide era. Transpl Cell Ther. 2021;27:590.e1–590.e8.

Article  CAS  Google Scholar